跳至主要内容
临床试验/CTRI/2020/06/025573
CTRI/2020/06/025573招募中3 期

Phase III trial of hypo-fractionated accelerated intensity modulated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed Glioblastoma (HYART-GBM) - HYART-GBM

AIIMS New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age 18 - 65 years
  • Patients of either sex will be included
  • Karnofsky performance score 70 and above
  • Biopsy proven Glioblastoma (WHO grade IV)
  • Baseline investigations [LFT, RFT, complete blood count] should be within normal limits Hemoglobin >10gm/dl, Platelet >100000, TLC-4000-11000
  • No history of prior anti-cancer treatment with radiotherapy, chemotherapy or surgery
  • The patient must sign an informed consent before entry into the study

排除标准

  • Age >65 years and <18 years
  • Previous history of nuero-surgery or radiotherapy
  • Recurrent or metastatic disease
  • Patients with significant co-morbid condition
  • History of previous malignancy
  • Performance score below 70
  • Unresectable disease
  • Not compliant for regular follow up

研究者

发起方
AIIMS New Delhi

相似试验